06.19.25 -- Cleaning Process Capability: Understanding Populations, Samples, And Sample Size Requirements

Review features that need to be considered to choose a vial adapter for cell and gene therapy drug products and a case study where vial adapter transfer devices have been used to extract lentiviruses.

Sterile connectors streamline cell and gene therapy processes while maintaining sterility. By withstanding extreme temperatures and cryoprotectants, they can ensure product viability during cryopreservation.

How can you leverage flow electroporation technology to drive your biologics development forward and deliver gram-scale transient protein production within two weeks?

Addressing critical hurdles in CAR-T cell production, this research demonstrates methods to enhance efficiency and reduce expenses for broader patient benefit.

Discover how AI can optimize processes, improve efficiency, and enhance the understanding of cellular processes, ultimately leading to more effective and personalized patient treatments.

Manufacturing operations are getting a boost thanks to single-use technologies, but how do biopharmaceutical manufacturers choose the right materials for constructing their single-use solutions?

With regulatory requirements and GMP recommendations trending towards less human interaction and more robotic automation, robotics is the way of the future for the ATMP industry.

What must we do as an industry to continue the momentum of cell and gene therapies and ensure these revolutionary treatments become a reality for patients who need them?

In this panel discussion, you’ll learn from experienced colleagues who share their approaches to capacity expansion and offer tips for your success.

Behind every life-saving cell therapy is a complex manufacturing journey. Examine the critical role of automation in overcoming production challenges and ensuring quality.

When it comes to process development, timing, technology, and partners all merit careful consideration. Explore expert insights into these three crucial factors.

New bioreactor technology provides an optimal environment for shear-sensitive cells, addressing key scale-up challenges for allogeneic therapies from research to commercial production.

Successfully bring your CGT products to market by joining industry experts as they discuss challenges in CGT process development.